Industrial scale high-throughput screening delivers multiple fast acting macrofilaricides

Rachel H. Clare, Catherine Bardelle, Paul Harper, W. David Hong, Ulf Börjesson, Kelly L. Johnston, Matthew Collier, Laura Myhill, Andrew Cassidy, Darren Plant, Helen Plant, Roger Clark, Darren A. N. Cook, Andrew Steven, John Archer, Paul McGillan, Sitthivut Charoensutthivarakul, Jaclyn Bibby, Raman Sharma, Gemma L. Nixon, Barton E. Slatko, Lindsey Cantin, Bo Wu, Joseph Turner, Louise Ford, Kirsty Rich, Mark Wigglesworth, Neil G. Berry, Paul M. O’Neill (), Mark J. Taylor and Stephen A. Ward ()
Additional contact information
Rachel H. Clare: Liverpool School of Tropical Medicine
Catherine Bardelle: AstraZeneca
Paul Harper: AstraZeneca
W. David Hong: University of Liverpool
Ulf Börjesson: AstraZeneca
Kelly L. Johnston: Liverpool School of Tropical Medicine
Matthew Collier: AstraZeneca
Laura Myhill: Liverpool School of Tropical Medicine
Andrew Cassidy: Liverpool School of Tropical Medicine
Darren Plant: AstraZeneca
Helen Plant: AstraZeneca
Roger Clark: AstraZeneca
Darren A. N. Cook: Liverpool School of Tropical Medicine
Andrew Steven: Liverpool School of Tropical Medicine
John Archer: Liverpool School of Tropical Medicine
Paul McGillan: University of Liverpool
Sitthivut Charoensutthivarakul: Liverpool School of Tropical Medicine
Jaclyn Bibby: University of Liverpool
Raman Sharma: Liverpool School of Tropical Medicine
Gemma L. Nixon: University of Liverpool
Barton E. Slatko: New England Biolabs, Inc
Lindsey Cantin: New England Biolabs, Inc
Bo Wu: New England Biolabs, Inc
Joseph Turner: Liverpool School of Tropical Medicine
Louise Ford: Liverpool School of Tropical Medicine
Kirsty Rich: AstraZeneca
Mark Wigglesworth: AstraZeneca
Neil G. Berry: University of Liverpool
Paul M. O’Neill: University of Liverpool
Mark J. Taylor: Liverpool School of Tropical Medicine
Stephen A. Ward: Liverpool School of Tropical Medicine

Nature Communications, 2019, vol. 10, issue 1, 1-8

Abstract: Abstract Nematodes causing lymphatic filariasis and onchocerciasis rely on their bacterial endosymbiont, Wolbachia, for survival and fecundity, making Wolbachia a promising therapeutic target. Here we perform a high-throughput screen of AstraZeneca’s 1.3 million in-house compound library and identify 5 novel chemotypes with faster in vitro kill rates (

Date: 2019
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-018-07826-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-018-07826-2

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-018-07826-2

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().